Zoetis Receives FDA EUA for Simparica Trio in Dogs
PARSIPPANY, N.J., August 13, 2026 Zoetis Inc. announced that the U.S. Food and Drug Administration has issued an Emergency...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PARSIPPANY, N.J., August 13, 2026 Zoetis Inc. announced that the U.S. Food and Drug Administration has issued an Emergency...
NEW HAVEN, Conn., July 6, 2026 Invivyd announced that the U.S. Food and Drug Administration (FDA) has issued a...
RAHWAY, N.J., June 12, 2026 The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™...
SILVER SPRING, Maryland, June 11, 2026 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization...
DULUTH, Ga., Feb. 5, 2026 — Boehringer Ingelheim Animal Health USA Inc. announced that the U.S. Food and Drug...
NORTH CHICAGO, Ill., October 29, 2025 — AbbVie Inc. (NYSE: ABBV) announced positive topline results from two replicate Phase...
INDIANAPOLIS, Ind., October 24, 2025 — In a landmark decision for veterinary medicine and regulatory preparedness, Elanco Animal Health...
